HRAS mutations are very common in cancer and G12D variant is primarily found in bladder urothelial carcinoma, cutaneous melanoma, infiltrating renal pelvis, ureter urothelial carcinoma, melanoma, and colorectal adenocarcinoma (The AACR Project GENIE Consortium et al., 2017). Here, HRAS is linked to neoplasm.